Cittadine Andrew 4
4 · Monopar Therapeutics · Filed Oct 2, 2024
Insider Transaction Report
Form 4
Cittadine Andrew
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2024-09-30+1,791→ 40,404 total - Tax Payment
Common Stock
2024-09-30$6.74/sh−535$3,606→ 39,869 total - Exercise/Conversion
Restricted Stock Units
2024-09-30−1,791→ 12,864 total→ Common Stock (1,791 underlying)
Footnotes (5)
- [F1]Effective on August 12, 2024, Monopar Therapeutics Inc effected a 5 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
- [F2]Represents shares acquired on vesting and settlement of restricted stock units.
- [F3]Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
- [F4]On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
- [F5]On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.